Vivos Therapeutics Exchanges $2.86 Million Of Debt For Shares; Stock Down

Vivos Therapeutics entered into 12 exchange agreements with Streeterville Capital on August 31, 2026, covering $2.86 million of outstanding principal under secured promissory obligations. The transaction signals a restructuring of existing debt, though the available article text does not disclose the exchange terms, resulting securities, or balance-sheet impact.